MX2022001721A - Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos. - Google Patents

Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos.

Info

Publication number
MX2022001721A
MX2022001721A MX2022001721A MX2022001721A MX2022001721A MX 2022001721 A MX2022001721 A MX 2022001721A MX 2022001721 A MX2022001721 A MX 2022001721A MX 2022001721 A MX2022001721 A MX 2022001721A MX 2022001721 A MX2022001721 A MX 2022001721A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
directed against
bispecific antibodies
antibodies directed
routes
Prior art date
Application number
MX2022001721A
Other languages
English (en)
Inventor
Jesper Valbjoern
Lene S Harlow
Jacob D Clausen
Mette H Jensen
Christian Cimander
Peter J Madsen
Shan Ren
Jesper Pass
Maria A C Wahlbom
Bolette Bjerregaard
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of MX2022001721A publication Critical patent/MX2022001721A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas mejoradas y formas unitarias de dosificación de anticuerpos biespecíficos CD3xCD20 y a rutas de administración.
MX2022001721A 2019-08-15 2020-08-14 Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos. MX2022001721A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19191964 2019-08-15
PCT/EP2020/072927 WO2021028587A1 (en) 2019-08-15 2020-08-14 Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses

Publications (1)

Publication Number Publication Date
MX2022001721A true MX2022001721A (es) 2022-03-11

Family

ID=67659000

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001721A MX2022001721A (es) 2019-08-15 2020-08-14 Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos.

Country Status (11)

Country Link
US (1) US20220411505A1 (es)
EP (1) EP4013509A1 (es)
JP (1) JP2022548823A (es)
KR (1) KR20220047808A (es)
CN (1) CN114555118A (es)
AU (1) AU2020328195A1 (es)
BR (1) BR112022002653A2 (es)
CA (1) CA3149333A1 (es)
IL (1) IL290512A (es)
MX (1) MX2022001721A (es)
WO (1) WO2021028587A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3176436A1 (en) * 2020-05-08 2021-11-11 Tahamtan Ahmadi Bispecific antibodies against cd3 and cd20
CN116472058A (zh) 2020-09-10 2023-07-21 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against CD3 and CD20 in combination therapy for the treatment of follicular lymphoma
CA3190349A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
BR112023004296A2 (pt) * 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma de célula b grande difusa em um indivíduo humano
EP4210743A1 (en) * 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
CA3214582A1 (en) * 2021-05-07 2022-11-10 Martin SAHLIN Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
BR112012026766B1 (pt) 2010-04-20 2021-11-03 Genmab A/S Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
AU2013221635B2 (en) * 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
KR102663073B1 (ko) * 2015-01-08 2024-05-07 젠맵 에이/에스 Cd3 및 cd20에 대항한 이중특이적 항체

Also Published As

Publication number Publication date
JP2022548823A (ja) 2022-11-22
EP4013509A1 (en) 2022-06-22
CA3149333A1 (en) 2021-02-18
US20220411505A1 (en) 2022-12-29
IL290512A (en) 2022-04-01
AU2020328195A1 (en) 2022-03-03
WO2021028587A1 (en) 2021-02-18
BR112022002653A2 (pt) 2022-05-03
KR20220047808A (ko) 2022-04-19
CN114555118A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2020007697A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos.
MX2022001721A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos.
EA202190808A2 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2018016364A (es) Anticuerpos anti-pd-l1.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
MX2018006477A (es) Anticuerpos y metodos de uso de estos.
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
JOP20200177A1 (ar) طرق علاج السرطان باستخدام الأجسام المضادة anti-pd-1 المناهضة
PH12020552154A1 (en) Compounds
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
CO2020012524A2 (es) Anticuerpos
EA202192405A1 (ru) Составы антител против il-36r
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MX2020009275A (es) Composiciones de anticuerpo anti-pd-1.
MX2021005085A (es) Formulacion de anticuerpo.
MX2019013753A (es) Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1.
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
CR20230525A (es) Anticuerpos anti-cd20 y estructuras car-t
WO2018087143A3 (en) Anti-pd-1 antibodies
MX2021012365A (es) Anticuerpos biespecificos.
PH12019502694A1 (en) Anti-trkb antibodies